Trastuzumab-emtansine induced pleural and pericardial effusions.
Fiche publication
Date publication
mai 2021
Journal
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Auteurs
Membres identifiés du Cancéropôle Est :
Pr SCHMITT Antonin, Dr MAYEUR Didier
Tous les auteurs :
Lombardi J, Lory P, Martin N, Mayeur D, Combret S, Grandvuillemin A, Boulay C, Schmitt A
Lien Pubmed
Résumé
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate which combine trastuzumab (T), a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), and a cytotoxic molecule derived from maytansine (DM1).
Mots clés
Pleural effusions, adverse drug reaction, oncology, pericardial effusion, trastuzumab-emtansine
Référence
J Oncol Pharm Pract. 2021 May 18;:10781552211015772